European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

• Published in: European heart journal. Quality of care & clinical outcomes Vol. 9; no. 1; pp. 1 - 7
• Main Authors: Lee, G A, Aktaa, S, Baker, E, Gale, C P, Yaseen, Israa F, Gulati, G, Asteggiano, R, Szmit, S, Cohen-Solal, A, Abdin, A, Jurczak, W, Garrido Lopez, P, Sverdlov, A L, Tocchetti, C G, Barac, A, Parrini, I, Zamorano, P, Iakobishvili, Z, Pudil, R, Badimon, L, Kirby, A M, Blaes, A H, Farmakis, D, Curigliano, G, Stephens, R, Lyon, A R, Lopez-Fernandez, T
• Format: Journal Article
• Language: English; Norwegian
• Published: England Oxford University Press 01.01.2023
• Subjects: Cancer therapies; Cardiology; Collaboration; Heart; Hematology; Humans; Medical Oncology; Medical research; Neoplasms - therapy; Oncology; Prevention; Quality Indicators, Health Care; Review; Side effects; Toxicity; Quality indicators; Cardio-oncology; Treatment; Cancer therapy-related cardiovascular toxicity; Outcomes; Assessment
• ISSN: 2058-5225; 2058-1742; 2058-1742
• DOI: 10.1093/ehjqcco/qcac070

Abstract Aims To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. Conclusion We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.